.

Summary:
Abiomed recently reported a strong Q4 with $124.7 million in revenue, representing a 33% growth. For the full fiscal year 2017, revenue was $445.3 million, a 35% increase. The company remains one of the fastest-growing, GAAP profitable medical device companies. Abiomed achieved multiple regulatory approvals and expanded its clinical evidence. The company has a solid balance sheet with $277 million in cash and no debt. They also have a strong intellectual property portfolio with 274 patents and 241 pending. The company plans to focus on growth in Protected PCI and AMI cardiogenic shock, aiming to improve clinical outcomes. They also anticipate launching the Impella RP in the U.S. in the second half of fiscal year 2018. The company is also focused on expanding its presence in Japan. The company is confident in its ability to continue creating a new era of medicine focused on heart recovery.
As a financial analyst adopting an 'overweight' investment stance, it is clear that Abiomed has strong financial metrics with steady revenue growth, a solid balance sheet, and a focus on expanding its product portfolio and global presence. These factors position the company for continued success and make it an attractive investment option.